Recombinant Human IL22 protein, N-His Tag
Product Description
Cat
IMP-2873
Official Symbol
IL22
Product Overview
Recombinant Human IL22 protein(Q9GZX6)(Ala34~Ile179), fused with N-terminal His Tag, was expressed in E. coli.
Expression System
E. coli
Species
Human
Tag
N-His Tag
Form
20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
Protein length
Asp2-Lys17
Purity
> 95%
Storage
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
Reconstitution
It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
Western Blot 1
Western Blot

SDS-PAGE
SDS-PAGE

Bioactivity-ELISA 1
The binding activity of IL22 with IL10Rb

Interleukin 22 (IL22) is a member of a group of cytokines called the IL-10 family or IL-10 superfamily, a class of potent mediators of cellular inflammatory responses. It shares use of IL-10R2 in cell signaling with other members of this family, IL-10, IL-26, IL-28A/B and IL-29. IL-22 is produced by activated NK and T cells and initiates innate immune responses against bacterial pathogens especially in epithelial cells such as respiratory and gut epithelial cells. IL-22 biological activity is initiated by binding to a cell-surface complex composed of IL-22R1 and IL-10R2 receptor chains and further regulated by interactions with a soluble binding protein. IL-22 can contribute to immune disease through the stimulation of inflammatory responses, S100s and defensins. IL-22 also promotes hepat°Cyte survival in the liver and epithelial cells in the lung and gut similar to IL-10. Besides, Interleukin 10 Receptor Beta (IL10Rb) has been identified as an interactor of IL22, thus a binding ELISA assay was conducted to detect the interaction of recombinant human IL22 and recombinant human IL10Rb. Briefly, IL22 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to IL10Rb-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-IL22 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of IL22 and IL10Rb was shown in Figure 1, and this effect was in a dose dependent manner.

Data Sheet MSDS
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Online Inquiry
Contact Info